Form 4: SOPHiA GENETICS CLO Sells Shares for Tax Obligations

SOPHiA GENETICS' Chief Legal Officer, Daan Van Well, sold 684 ordinary shares for $4.7865 per share to cover tax liabilities from RSU vesting.

Summary

• Daan Van Well, Chief Legal Officer of SOPHiA GENETICS SA, reported the sale of 684 ordinary shares.
• The transaction occurred on March 19, 2026, at a weighted average price of $4.7865 per share.
• The shares were sold in multiple transactions with prices ranging from $4.69 to $4.87, inclusive.
• The purpose of the sale was to satisfy tax obligations related to the vesting of restricted stock units (RSUs) on March 18, 2026.
• The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating it was not a discretionary trade.
• Following this transaction, Daan Van Well directly beneficially owns 261,238 ordinary shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it represents a reduction in insider ownership, the sale was for tax purposes related to RSU vesting and executed under a 10b5-1 plan, which mitigates concerns about discretionary selling.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating a non-discretionary, planned transaction rather than a reactive sale based on new information.

Negatives

• An officer of the company reduced their direct beneficial ownership by 684 shares, even if for tax purposes.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax obligations from RSU vesting and executed under a 10b5-1 plan, are common occurrences in the biotechnology and healthcare technology sectors. These types of sales are generally viewed as routine administrative events rather than indicators of management's sentiment about the company's future prospects.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature of the sale under a 10b5-1 plan suggests no negative implications for company outlook.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Legal Officer to cover tax liabilities associated with RSU vesting. Such transactions, especially when executed under a 10b5-1 plan, are common and generally do not reflect a change in the insider's confidence in the company's future. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation, leading to a 'hold' stance.

Keywords

SOPHiA GENETICS, SOPH, Form 4, Insider Trading, Share Sale, Restricted Stock Units, RSU Vesting, Tax Obligations, 10b5-1 Plan, Daan Van Well